Skip to main content
ALBOinactive

ALBIREO PHARMA, INC.

Biopharma developer (SEC filing verified)·Commercial·CEO: Albireo Pharma
Gastroenterology

ALBO evidence brief

What we can confirm

BioSniper Score:
8.6 / 10
Lead Asset:
a2342 (Preclinical)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 8.6 / 10 · Lead Asset: a2342 (Preclinical)
BioSniper AIPage evidence connected

Prepared research question

What matters most for ALBO—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

8.6/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

a2342 (Preclinical)

Next Catalyst

—

Tracking 4 pipeline candidates for ALBIREO PHARMA, INC..

Run ALBIREO PHARMA, INC. through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available ALBIREO PHARMA, INC. facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth7.2

4 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is ALBIREO PHARMA, INC.'s lead drug candidate?

ALBIREO PHARMA, INC.'s most advanced tracked candidate is a2342 (Preclinical) for adult viral and liver diseases.

Who is the CEO of ALBIREO PHARMA, INC.?

Albireo Pharma is the chief executive officer of ALBIREO PHARMA, INC. (ALBO).

What therapeutic areas does ALBIREO PHARMA, INC. focus on?

ALBIREO PHARMA, INC. develops therapies across Gastroenterology.

923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.